Top 100 Agencies: Centron

Share this article:
Work for the JED Foundation's "Love is Louder" campaign
Work for the JED Foundation's "Love is Louder" campaign

Centron president and CEO Marcia McLaughlin is very excited to talk to MM&M this year from the agency's new, much larger office in Manhattan. Continued growth of between 10% and 20% last year prompted the move, which has “infused the agency with a sense of rebirth” as it enters its eighth year.

“There's nothing like a move to bigger, more beautiful space to ignite an agency,” McLaughlin says. “The day we moved I told everyone to go home at 3 p.m. Half of my staff came straight to the new office and stayed until 3 a.m. helping move. It speaks to the camaraderie this agency has—even if people aren't needed, they'll show up to help.”

Indeed, Centron is tight-knit. McLaughlin and chief creative officer Michael Metelenis worked together for 20 years at Omnicom shop KPR (which folded in 2008) before founding Centron, and many of the agency's senior leaders have long-standing working relationships. Newcomer Rob Perota joined last year from CDM as EVP, executive creative director.

“Bringing in someone who none of us knew isn't necessarily easily, but Rob's got the right personality,” McLaughlin says. “He's really inspired creative and upped our game.”

Overall, staff increased by five to 75 last year. There are 78 now and six openings across all levels.

McLaughlin also cites the agency's work, which includes professional advertising and medical education AOR status for Shionogi's new vulvar and vaginal atrophy (VVA) treatment Osphena. “Osphena is a ground-breaking product, “ she says. “VVA impacts the lives of many women and bringing this product to the market is a defining moment for Shionogi. It's been a wonderful experience for Centron to be part of the launch as AOR.”

Much new business came on last year, with no losses. AbbVie awarded large-scale professional project work on its men's health franchise and promotion work for its hypogonadism clinical educators program. Along with HealthSTAR Vivactis Global Network (of which McLaughlin is president), Centron won US project work on GSK's Flolan (PPH). New client Taro awarded project work on Ovide (lice). The agency also began pro bono work for JED Foundation (suicide prevention).

Relationships expanded with Bayer, Eisai, OraPharma, Merz and Forest. Bayer assigned positioning project work on oncology product Stivarga, a follow-up product to Nexavar for which Centron is AOR. Eisai awarded work on two CINV products.

The agency pitched and won AOR status on carpirazine (a Ph. III antipsychotic) from long-time client Forest. OraPharma awarded medical education and advertising AOR status on Ossix Plus. Following the successful launch of Naftin 2% cream, Merz awarded Centron AOR status to launch Naftin 2% gel.

The agency is mostly pitching AOR work, which McLaughlin says is “bigger, broader and more integrated” now. She also reports increasing competition with large network agencies.

“Mid-size pharma companies call in mid-size agencies and usually one very large network agency for pitches,” she says. “The large network agency presents a lot of bells and whistles, and the marketing directors are impressed except their budget could never afford all those bells and whistles. More often we're competing with large network agencies that are looking for business beyond big pharma clients as procurement makes winning more difficult for them.”

Revenue is tracking up about 10%. Continuing to build global business through the HealthSTAR Vivactis Global Network is a priority.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.